Biogen Options Trading: A Deep Dive into Market Sentiment - Biogen ( NASDAQ:BIIB )
High-rolling investors have positioned themselves bullish on Biogen ( NASDAQ:BIIB ) , and it's important for retail traders to take note. \This activity came to our attention today through Benzinga's tracking of publicly available options data.
Biogen and Stoke Therapeutics Announce Publication of Two-Year Natural History Data Demonstrating the Severity of Dravet Syndrome, Including Frequent Seizures and Significant Cognitive and Behavioral Impairments - Stoke Therapeutics ( NASDAQ:STOK ) , Biogen ( NASDAQ:BIIB )
- Despite treatment with standard-of-care anti-seizure medicines, children with Dravet syndrome experienced high seizure burden and plateaued in neurodevelopment, resulting in a widening gap relative to children with typical development -
High Dose Regimen of Nusinersen Receives Positive CHMP Opinion for the Treatment of Spinal Muscular Atrophy - Ionis Pharmaceuticals ( NASDAQ:IONS ) , Biogen ( NASDAQ:BIIB )
Positive CHMP opinion is based on data from the DEVOTE study which evaluated the high dose regimen of nusinersen in treatment-naive participants and those transitioning from the currently approved 12mg dose regimen1 Final European Commission decision expected in January 2026
Biogen Completes Acquisition of Alcyone Therapeutics - Ionis Pharmaceuticals ( NASDAQ:IONS ) , Biogen ( NASDAQ:BIIB )
CAMBRIDGE, Mass., Nov. 14, 2025 ( GLOBE NEWSWIRE ) -- Biogen Inc. ( NASDAQ:BIIB ) has completed the acquisition of Alcyone Therapeutics, a clinical-stage biotechnology company known for its innovative CNS therapy delivery solutions, such as the ThecaFlex DRx™ drug delivery system.
Biogen Completes Acquisition of Alcyone Therapeutics
CAMBRIDGE, Mass., Nov. 14, 2025 ( GLOBE NEWSWIRE ) -- Biogen Inc. ( Nasdaq: BIIB ) has completed the acquisition of Alcyone Therapeutics, a clinical-stage biotechnology company known for its innovative CNS therapy delivery solutions, such as the ThecaFlex DRx™ drug delivery system.
"LEQEMBI®" ( lecanemab ) IV Maintenance Dosing for the Treatment of Early Alzheimer's Disease Approved in the United Kingdom
TOKYO and CAMBRIDGE, Mass., Nov. 13, 2025 ( GLOBE NEWSWIRE ) -- Eisai Co., Ltd. ( Headquarters: Tokyo, CEO: Haruo Naito, "Eisai" ) and Biogen Inc. ( Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, "Biogen" ) announced today that humanized anti- ...
"LEQEMBI®" ( lecanemab ) IV Maintenance Dosing for the Treatment of Early Alzheimer's Disease Approved in the United Kingdom - Biogen ( NASDAQ:BIIB )
TOKYO and CAMBRIDGE, Mass., Nov. 13, 2025 ( GLOBE NEWSWIRE ) -- Eisai Co., Ltd. ( Headquarters: Tokyo, CEO: Haruo Naito, "Eisai" ) and Biogen Inc. ( NASDAQ:BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A.
What the Options Market Tells Us About Biogen - Biogen ( NASDAQ:BIIB )
Investors with a lot of money to spend have taken a bullish stance on Biogen ( NASDAQ:BIIB ) . We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga. Whether these are institutions or just wealthy individuals, we don't know.
Shine a Light on Healthcare ETFs Amid National Alzheimer's Awareness Month
As National Alzheimer's Awareness Month spotlights new treatments, healthcare ETFs like XLV and VHT might gain fresh investor appeal.
Should Pacer US Small Cap Cash Cows ETF ( CALF ) Be on Your Investing Radar?
Style Box ETF report for CALF ...
DNLI Posts Narrower-Than-Expected Q3 Loss, Advances MPS IIIA Drug
Denali's Q3 loss widens year over year as expenses rise, while the FDA delays its review of the firm???s key Hunter syndrome therapy to 2026.
Prelude Therapeutics Announces Strategic Business Update
Prelude to prioritize development of mutant selective JAK2V617F JH2 inhibitor and KAT6A selective degrader programs ...
Prelude Therapeutics Announces Strategic Business Update - Prelude Therapeutics ( NASDAQ:PRLD )
Prelude to prioritize development of mutant selective JAK2V617F JH2 inhibitor and KAT6A selective degrader programs Pausing further clinical development of SMARCA2 selective degrader programs
Gene and Cell Therapies Emerge as Front-Runners in Neurology Innovation, with High Expectations in ALS, Parkinson's, and Neuroimmune Disorders
EXTON, PA, Nov. 03, 2025 ( GLOBE NEWSWIRE ) -- Spherix Global Insights' latest Special Topix™: Neurology Pipeline Opportunities 2025 ( US ) service captures forward-looking insights from 79 U.S. neurologists across five key neurological conditions-Amyotrophic Lateral Sclerosis ( ALS ) , ...
Biogen to Highlight Scientific Progress in Rare Kidney Disease at American Society of Nephrology ( ASN ) Kidney Week 2025 - Biogen ( NASDAQ:BIIB )
Oral presentation to share first-of-its-kind longitudinal gene expression data in IgA nephropathy, unveiling novel insights into the mechanism of action of felzartamab and advancing the understanding of its disease modifying potential
Biogen to Highlight Scientific Progress in Rare Kidney Disease at American Society of Nephrology ( ASN ) Kidney Week 2025
CAMBRIDGE, Mass., Nov. 03, 2025 ( GLOBE NEWSWIRE ) -- Biogen Inc. ( Nasdaq: BIIB ) - will present new data from its felzartamab clinical development programs at Kidney Week 2025, the American Society of Nephrology's ( ASN ) annual meeting, taking place November 5-9 in Houston, Texas.
BIIB Beats on Q3 Earnings & Sales, Stock Down on Lowered '25 EPS View
Biogen's Q3 earnings and sales top estimates on strong drug demand, but shares slide after the company cuts its 2025 EPS forecast.
Ionis Beats Q3 Earnings & Sales Estimates, Raises 2025 Outlook
IONS' Q3 results top estimates as robust Tryngolza and Wainua sales drive revenue growth. The company raises its 2025 outlook for the third time this year.
Biogen Inc. ( BIIB ) Q3 Earnings and Revenues Top Estimates
Biogen (BIIB) delivered earnings and revenue surprises of +23.65% and +8.31%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
Positive phase III results for Roche's Gazyva/Gazyvaro in children and young adults with idiopathic nephrotic syndrome
Basel, 28 October 2025 - Roche ( SIX: RO, ROG. OTCQX: RHHBY ) announced today statistically significant and clinically meaningful results from the phase III INShore study of Gazyva®/Gazyvaro® ( obinutuzumab ) in children and young adults ( aged >= 2-25 years ) with idiopathic nephrotic syndrome ( ...
Analysts Estimate Castle Biosciences, Inc. ( CSTL ) to Report a Decline in Earnings: What to Look Out for
Castle Biosciences (CSTL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Health Canada Grants Authorization for "LEQEMBI®" ( lecanemab ) for the Treatment of Early Alzheimer's Disease
In Canada, lecanemab is indicated for the treatment of adult patients with a clinical diagnosis of mild cognitive impairment or mild dementia due to Alzheimer's disease ( early AD ) who are apolipoprotein E ε4 ( ApoE ε4* ) non-carriers or heterozygotes and who have confirmed amyloid pathology In ...
Biogen's Immunology Pipeline Has Long-Term Potential: Analyst - Biogen ( NASDAQ:BIIB )
On Friday, Biogen Inc. ( NASDAQ:BIIB ) and Vanqua Bio announced a license agreement granting Biogen exclusive worldwide rights to Vanqua's preclinical, oral C5aR1 antagonist. The agreement strengthens Biogen's immunology.
Will Biogen Beat on Q3 Earnings? Leqembi, Skyclarys Could Hold the Key
Biogen is expected to top earnings forecasts again as new products offset declining multiple sclerosis drug sales.
Biogen Licenses Oral C5aR1 Antagonist from Vanqua Bio to Expand Immunology Portfolio
CAMBRIDGE, Mass. and CHICAGO, Oct. 24, 2025 ( GLOBE NEWSWIRE ) -- Biogen Inc. ( Nasdaq: BIIB ) and Vanqua Bio today announced a license agreement granting Biogen exclusive worldwide rights to Vanqua's preclinical, oral C5aR1 antagonist.
Biogen Inc. ( BIIB ) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
Biogen (BIIB) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Cassava Sciences Appoints Dawn C. Bir to the Board of Directors
AUSTIN, Texas, Oct. 22, 2025 ( GLOBE NEWSWIRE ) -- Cassava Sciences, Inc. ( NASDAQ: SAVA, "Cassava", the "Company" ) , a biotechnology company focused on developing novel, investigational treatments for central nervous system ( CNS ) disorders such as Tuberous Sclerosis Complex ( TSC ) -related ...
Cassava Sciences Appoints Dawn C. Bir to the Board of Directors - Cassava Sciences ( NASDAQ:SAVA )
AUSTIN, Texas, Oct. 22, 2025 ( GLOBE NEWSWIRE ) -- Cassava Sciences, Inc. ( NASDAQ:SAVA, "Cassava", the "Company" ) ) , a biotechnology company focused on developing novel, investigational treatments for central nervous system ( CNS ) disorders such as Tuberous Sclerosis Complex ( TSC ) -related ...
Biogen to Present Additional Results from Phase 3 Study of Dapirolizumab Pegol in Systemic Lupus Erythematosus at ACR Convergence 2025
CAMBRIDGE, Mass., Oct. 22, 2025 ( GLOBE NEWSWIRE ) -- Biogen Inc. ( Nasdaq: BIIB ) today announced upcoming presentations from studies evaluating dapirolizumab pegol ( DZP ) , a novel Fc-free anti-CD40L drug candidate, in systemic lupus erythematosus ( SLE ) to be presented at the American ...
Roche's Gazyva Secures FDA Nod for Label Expansion in Lupus Nephritis
RHHBY secures FDA approval to expand Gazyva's label for treating lupus nephritis, offering patients a faster and more convenient treatment option.
Climb Bio Names Adam Villa as SVP, Technical Operations and Ashley Jones as SVP, People & Workforce Strategy
WELLESLEY HILLS, Mass., Oct. 21, 2025 ( GLOBE NEWSWIRE ) -- Climb Bio, Inc. ( Nasdaq: CLYM ) , a clinical-stage biotechnology company developing therapeutics for immune-mediated diseases, today announced that it has strengthened its leadership team with the appointments of Adam Villa as Senior ...
Abeona Therapeutics® Appoints James A. Gow, MD, MBA, MS, MHCM, as Senior Vice President, Head of Clinical Development & Medical Affairs
CLEVELAND, Oct. 20, 2025 ( GLOBE NEWSWIRE ) -- Abeona Therapeutics Inc. ( Nasdaq: ABEO ) , a commercial-stage biopharmaceutical company developing cell and gene therapies for serious diseases, today announced the appointment of James A.
FDA approves Roche's Gazyva/Gazyvaro for the treatment of lupus nephritis
Basel, 20 October 2025 - Roche ( SIX: RO, ROG. OTCQX: RHHBY ) announced today that the US Food and Drug Administration ( FDA ) has approved Gazyva®/Gazyvaro® ( obinutuzumab ) for the treatment of adult patients with active lupus nephritis ( LN ) who are receiving standard therapy, as well as a ...
J.L. Bainbridge Exits Most of Biogen Stake as Biotech Stock Eyes Turnaround
Florida-based wealth advisory J. L. Bainbridge & Co. sold 119,376 shares of Biogen ( NASDAQ:BIIB ) during the third quarter for an estimated $16.1 million.In a quarterly disclosure filed with the Securities and Exchange Commission on Friday, J. L.
CHMP recommends EU approval of Roche's Gazyva/Gazyvaro for lupus nephritis
Basel, 17 October, 2025 - Roche ( SIX: RO, ROG. OTCQX: RHHBY ) announced today that the European Medicines Agency's Committee for Medicinal Products for Human Use ( CHMP ) has recommended the approval of Gazyva®/Gazyvaro® ( obinutuzumab ) in combination with mycophenolate mofetil ( MMF ) for the ...
Small-Cap Biotech Climb Bio's Lead Drug Candidate Has Larger Long-Term Opportunity - Climb Bio ( NASDAQ:CLYM )
William Blair initiated coverage for Climb Bio ( NASDAQ:CLYM ) , citing the potential of the company's budoprutug, under development for autoimmune indications, including: Phase 1b/2a immune thrombocytopenia ( ITP ) trial FPI achieved, enrollment ongoing.
CD40 Targeting Therapy Clinical Trials Anti CD40 Antibody Therapy Market Opportunity Assessment Insight
Delhi, Oct. 14, 2025 ( GLOBE NEWSWIRE ) -- Global CD40 Targeted Therapies Clinical Trials, Therapeutic Approaches, Proprietary Technology Platforms & Market Opportunity Insight 2026 Report Findings and Highlights: First CD40 Targeted Therapy Approval Expected By 2027
FDA Extends Review of DNLI's Hunter Syndrome Drug by Three Months
Denali Therapeutics faces an FDA review delay for its Hunter syndrome drug, pushing potential approval of tividenofusp alfa to April 2026.
LEQEMBI® IQLIK™ ( lecanemab-irmb ) Subcutaneous Autoinjector Named to TIME's "Best Inventions of 2025"
TOKYO and CAMBRIDGE, Mass., Oct. 13, 2025 ( GLOBE NEWSWIRE ) -- Eisai Co., Ltd. ( Headquarters: Tokyo, CEO: Haruo Naito, "Eisai" ) and Biogen Inc. ( Nasdaq: BIIB, Headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, "Biogen" ) announced today that LEQEMBI® IQLIK™, a ...
LEQEMBI® IQLIK™ ( lecanemab-irmb ) Subcutaneous Autoinjector Named to TIME's "Best Inventions of 2025" - Biogen ( NASDAQ:BIIB )
TOKYO and CAMBRIDGE, Mass., Oct. 13, 2025 ( GLOBE NEWSWIRE ) -- Eisai Co., Ltd. ( Headquarters: Tokyo, CEO: Haruo Naito, "Eisai" ) and Biogen Inc. ( NASDAQ:BIIB, Headquarters: Cambridge, Massachusetts, CEO: Christopher A.
Can Biogen Stock Rebound as New Drugs Aim to Offset MS Sales Declines?
Biogen's new drugs Leqembi, Skyclarys and Zurzuvae are driving fresh momentum, but MS and Spinraza declines cloud its growth path.
Biogen and Stoke Therapeutics Present New Data at the 54th Child Neurology Society ( CNS ) Annual Meeting that Support the Potential of Zorevunersen as a Disease-Modifying Medicine for Dravet Syndrome
- An analysis designed to evaluate the potential effects of the Phase 3 zorevunersen dosing regimen showed continuing improvements in cognition and behavior at 2 years. results contrast with minimal change in natural history ...
Can BMYs Neuroscience Portfolio Help to Diversify Its Business?
Bristol Myers gains FDA Fast Track status for its Alzheimer's antibody BMS-986446 as Cobenfy drives early sales and pipeline momentum.
Eisai and Biogen Announce U.S. Availability of LEQEMBI® IQLIK™ ( lecanemab-irmb ) Subcutaneous Injection Maintenance Dose for Treatment of Early Alzheimer's Disease - Biogen ( NASDAQ:BIIB )
New LEQEMBI Companion™ program launched to expand helpful resources for patients throughout the treatment journey, including Nurse Educators who can provide patients with injection training, and an injection tracking tool and more LEQEMBI IQLIK, approved by the U.S.
Eisai and Biogen Announce U.S. Availability of LEQEMBI® IQLIK™ ( lecanemab-irmb ) Subcutaneous Injection Maintenance Dose for Treatment of Early Alzheimer's Disease
New LEQEMBI Companion™ program launched to expand helpful resources for patients throughout the treatment journey, including Nurse Educators who can provide patients with injection training, and an injection tracking tool and more ...
Is Invesco Biotechnology & Genome ETF ( PBE ) a Strong ETF Right Now?
Smart Beta ETF report for ...
Here's Why You Should Retain BXP Stock in Your Portfolio Now
BXP is likely to gain from a premium office portfolio, a diverse tenant base and strong lab asset demand despite high debt and interest expenses.
As Roche/Genentech's Obinutuzumab ( Gazyva ) Nears FDA Decision, Spherix Global Insights White Paper Reveals Keys to Successful Lupus Product Launches
EXTON, PA, Oct. 02, 2025 ( GLOBE NEWSWIRE ) -- Spherix Global Insights has released a new white paper, Navigating the Evolving SLE/Lupus Nephritis Landscape: Keys to Successful Product Launches, which explores the critical factors shaping success in one of the most complex autoimmune markets.
Trump's pharmaceutical tariff threat loses bite after Pfizer deal reassures drugmakers
Pfizer's deal with Trump was a relief to the pharma industry, signaling that drugmakers could strike similar deals that would make them immune to tariffs.
Climb Bio Appoints Susan Altschuller, Ph.D., MBA as Chief Financial Officer
WELLESLEY HILLS, Mass., Oct. 01, 2025 ( GLOBE NEWSWIRE ) -- Climb Bio, Inc. ( Nasdaq: CLYM ) , a clinical-stage biotechnology company developing therapeutics for immune-mediated diseases, today announced that it has strengthened its leadership team with the addition of Susan Altschuller, Ph.D., ...
